Want to see AU:IMU full AI Analyst Report?
IMU Stock Chart & Stats
AU$0.09
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.09
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.46
Previous CloseN/A
Volume4.23M
Average Volume (3M)877.83K
Market Cap
AU$40.16M
Enterprise ValueAU$97.38
Total Cash (Recent Filing)AU$14.14M
Total Debt (Recent Filing)AU$5.02M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Sep 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding489,719,850
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$2.50M
Bulls Say, Bears Say
Bulls Say
Conservative Capital Structure (low Leverage)The balance sheet shows low leverage (debt-to-equity 0.24) and a moderate equity ratio, which reduces interest burden and solvency risk. A conservative capital structure improves flexibility to raise equity or form partnerships to fund multi-month clinical programs without immediate liquidity stress.
Focused Clinical-stage Immuno-oncology PipelineImugene’s strategic concentration on immuno-oncology and advancing candidates through preclinical and clinical stages aligns with structural growth in cancer immunotherapies. Focused R&D can create significant long-term value on successful trials and supports clear program prioritization across limited resources.
Free Cash Flow Exceeds Reported Net IncomeA FCF-to-net-income ratio above 1.0 indicates free cash flow exceeded net income, suggesting disciplined capex and the presence of non‑cash accounting items. This implies some ability to generate or preserve cash relative to reported losses, which can extend runway or support targeted program spending.
Bears Say
Severe Revenue DeclineA reported revenue decline of -338.95% reflects a dramatic loss of top-line activity and indicates the company lacks recurring product revenue. This structural weakness forces dependence on external financing, reduces bargaining power with partners, and strains long-term funding for clinical programs.
Sustained Unprofitability And Negative MarginsDeep negative net margin and negative EBIT/EBITDA highlight persistent operating losses and inefficiencies. Ongoing unprofitability erodes shareholder equity over time, necessitates repeated capital raises, and constrains the company’s ability to scale R&D or advance multiple programs without dilution.
Negative Operating Cash Flow (cash Burn)Negative operating cash flow signals core operations consume cash, creating structural cash burn. This increases execution risk for clinical timelines, heightens reliance on capital markets or partners, and can force reprioritization of programs if additional financing is delayed or unavailable.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.08 and its highest was AU$0.46 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$40.16M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 8 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Undervalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.04.
How many shares outstanding does Imugene have?
Imugene has 489,719,850 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (177.78% Upside)
AU$0.25 (177.78% Upside)
Blogger Sentiment
Neutral
AU:IMU Sentiment 56%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
IMU Stock 12 Month Forecast
Average Price Target
AU$0.25
▲(177.78% Upside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―